{"id":3205,"date":"2017-09-20T15:52:34","date_gmt":"2017-09-20T14:52:34","guid":{"rendered":"https:\/\/lscconnect.com\/consultantconnect\/takeda-ireland-bright-future-ahead\/"},"modified":"2020-12-15T17:42:13","modified_gmt":"2020-12-15T17:42:13","slug":"takeda-ireland-bright-future-ahead","status":"publish","type":"post","link":"https:\/\/lscconnect.com\/consultantconnect\/blog\/2017\/09\/20\/takeda-ireland-bright-future-ahead\/","title":{"rendered":"Takeda Ireland bright future ahead"},"content":{"rendered":"<p>While the news headlines relating to Takeda appear to be negative the underlying facts suggest otherwise. Profits to March 2017 were \u20ac5.2 million, down from \u20ac102 million a year earlier (\u20ac96.8 million reduction).<\/p>\n<p>This decline was principally made up of two factors:<br \/>\n&#8211; Expenses of \u20ac25.2 million related to the drug Vocinti which was cancelled during clinical trials<br \/>\n&#8211; A significant increase in administration expenses linked to intra-company transactions. Such costs jumped from \u20ac151 million to \u20ac247 million last year (\u20ac97 million increase in costs).<\/p>\n<p>A drug cancellation during clinical trials and changes in intra-company accounting actually hide a very positive picture for Takeda in Ireland which include:<br \/>\n&#8211; An increase in sales of products produced in Ireland from \u20ac357.5 million to \u20ac384.9 million (7.6% increase)<br \/>\n&#8211; The continued advancement of the GCP2 new production facility project for NINLARO in Grangecastle. The new production facility is of strategic importance to Takeda and will be unique in that it will house the Drug Substance, Drug Product, Primary and Secondary Packaging and QC processes all under one roof.<br \/>\n&#8211; An increase in R&amp;D staff spend in the Irish operations to \u20ac3.98 million<\/p>\n<p>Sometimes a headline can be misleading! <a href=\"https:\/\/www.irishtimes.com\/business\/health-pharma\/profits-slump-as-takeda-s-irish-subsidiary-records-384m-in-revenues-1.3255227\" target=\"_blank\" rel=\"noopener\">Click here to read the original article.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>While the news headlines relating to Takeda appear to be negative the underlying facts suggest otherwise. Profits to March 2017 were \u20ac5.2 million, down from \u20ac102 million a year earlier (\u20ac96.8 million reduction). This decline was principally made up of two factors: &#8211; Expenses of \u20ac25.2 million related to the drug Vocinti which was cancelled [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"passster_activate_protection":false,"passster_protect_child_pages":"","passster_protection_type":"password","passster_password":"","passster_activate_overwrite_defaults":"","passster_headline":"","passster_instruction":"","passster_placeholder":"","passster_button":"","passster_id":"","passster_activate_misc_settings":"","passster_redirect_url":"","passster_hide":"no","passster_area_shortcode":"","footnotes":""},"categories":[111,102,92,97,101,94,110,108],"tags":[550,635,650,676,718],"table_tags":[],"class_list":["post-3205","post","type-post","status-publish","format-standard","hentry","category-biopharma","category-biotech","category-experienced-contract","category-industry","category-life-sciences","category-news","category-pharmaceutical","category-quality-control-laboratory","tag-life-science-industry-news","tag-pharma","tag-pharma-news","tag-qc","tag-takeda-ireland"],"acf":{"mark_this_resource_as_exclusive":null,"short_description":null,"card_cta_text":null,"rf_displayopts_sitemap_hide":null},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Takeda Ireland bright future ahead - LSC Consultant Connect<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda Ireland bright future ahead - LSC Consultant Connect\" \/>\n<meta property=\"og:description\" content=\"While the news headlines relating to Takeda appear to be negative the underlying facts suggest otherwise. Profits to March 2017 were \u20ac5.2 million, down from \u20ac102 million a year earlier (\u20ac96.8 million reduction). This decline was principally made up of two factors: &#8211; Expenses of \u20ac25.2 million related to the drug Vocinti which was cancelled [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lscconnect.com\/consultantconnect\/blog\/2017\/09\/20\/takeda-ireland-bright-future-ahead\/\" \/>\n<meta property=\"og:site_name\" content=\"LSC Consultant Connect\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-20T14:52:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-12-15T17:42:13+00:00\" \/>\n<meta name=\"author\" content=\"granitewordpress\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"granitewordpress\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lscconnect.com\/consultantconnect\/blog\/2017\/09\/20\/takeda-ireland-bright-future-ahead\/\",\"url\":\"https:\/\/lscconnect.com\/consultantconnect\/blog\/2017\/09\/20\/takeda-ireland-bright-future-ahead\/\",\"name\":\"Takeda Ireland bright future ahead - LSC Consultant Connect\",\"isPartOf\":{\"@id\":\"https:\/\/lscconnect.com\/consultantconnect\/#website\"},\"datePublished\":\"2017-09-20T14:52:34+00:00\",\"dateModified\":\"2020-12-15T17:42:13+00:00\",\"author\":{\"@id\":\"https:\/\/lscconnect.com\/consultantconnect\/#\/schema\/person\/717681c4080cf795ecacb66665f0eef4\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lscconnect.com\/consultantconnect\/blog\/2017\/09\/20\/takeda-ireland-bright-future-ahead\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lscconnect.com\/consultantconnect\/#website\",\"url\":\"https:\/\/lscconnect.com\/consultantconnect\/\",\"name\":\"LSC Consultant Connect\",\"description\":\"Life Science Consultants - Contract Jobs in Life Sciences | LSC\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lscconnect.com\/consultantconnect\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/lscconnect.com\/consultantconnect\/#\/schema\/person\/717681c4080cf795ecacb66665f0eef4\",\"name\":\"granitewordpress\",\"url\":\"https:\/\/lscconnect.com\/consultantconnect\/blog\/author\/granitewordpress\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Takeda Ireland bright future ahead - LSC Consultant Connect","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Takeda Ireland bright future ahead - LSC Consultant Connect","og_description":"While the news headlines relating to Takeda appear to be negative the underlying facts suggest otherwise. Profits to March 2017 were \u20ac5.2 million, down from \u20ac102 million a year earlier (\u20ac96.8 million reduction). This decline was principally made up of two factors: &#8211; Expenses of \u20ac25.2 million related to the drug Vocinti which was cancelled [&hellip;]","og_url":"https:\/\/lscconnect.com\/consultantconnect\/blog\/2017\/09\/20\/takeda-ireland-bright-future-ahead\/","og_site_name":"LSC Consultant Connect","article_published_time":"2017-09-20T14:52:34+00:00","article_modified_time":"2020-12-15T17:42:13+00:00","author":"granitewordpress","twitter_card":"summary_large_image","twitter_misc":{"Written by":"granitewordpress","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/lscconnect.com\/consultantconnect\/blog\/2017\/09\/20\/takeda-ireland-bright-future-ahead\/","url":"https:\/\/lscconnect.com\/consultantconnect\/blog\/2017\/09\/20\/takeda-ireland-bright-future-ahead\/","name":"Takeda Ireland bright future ahead - LSC Consultant Connect","isPartOf":{"@id":"https:\/\/lscconnect.com\/consultantconnect\/#website"},"datePublished":"2017-09-20T14:52:34+00:00","dateModified":"2020-12-15T17:42:13+00:00","author":{"@id":"https:\/\/lscconnect.com\/consultantconnect\/#\/schema\/person\/717681c4080cf795ecacb66665f0eef4"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lscconnect.com\/consultantconnect\/blog\/2017\/09\/20\/takeda-ireland-bright-future-ahead\/"]}]},{"@type":"WebSite","@id":"https:\/\/lscconnect.com\/consultantconnect\/#website","url":"https:\/\/lscconnect.com\/consultantconnect\/","name":"LSC Consultant Connect","description":"Life Science Consultants - Contract Jobs in Life Sciences | LSC","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lscconnect.com\/consultantconnect\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/lscconnect.com\/consultantconnect\/#\/schema\/person\/717681c4080cf795ecacb66665f0eef4","name":"granitewordpress","url":"https:\/\/lscconnect.com\/consultantconnect\/blog\/author\/granitewordpress\/"}]}},"_links":{"self":[{"href":"https:\/\/lscconnect.com\/consultantconnect\/wp-json\/wp\/v2\/posts\/3205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lscconnect.com\/consultantconnect\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lscconnect.com\/consultantconnect\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lscconnect.com\/consultantconnect\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/lscconnect.com\/consultantconnect\/wp-json\/wp\/v2\/comments?post=3205"}],"version-history":[{"count":1,"href":"https:\/\/lscconnect.com\/consultantconnect\/wp-json\/wp\/v2\/posts\/3205\/revisions"}],"predecessor-version":[{"id":4114,"href":"https:\/\/lscconnect.com\/consultantconnect\/wp-json\/wp\/v2\/posts\/3205\/revisions\/4114"}],"wp:attachment":[{"href":"https:\/\/lscconnect.com\/consultantconnect\/wp-json\/wp\/v2\/media?parent=3205"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lscconnect.com\/consultantconnect\/wp-json\/wp\/v2\/categories?post=3205"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lscconnect.com\/consultantconnect\/wp-json\/wp\/v2\/tags?post=3205"},{"taxonomy":"table_tags","embeddable":true,"href":"https:\/\/lscconnect.com\/consultantconnect\/wp-json\/wp\/v2\/table_tags?post=3205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}